Development of a novel UHPLC-MS/MS method for quantitative analysis of pirtobrutinib in rat plasma: application to pharmacokinetic study

Authors: Meijuan Zhang, Jingxuan Wu, Jiangshuo Li, Hang Yin, Mengyu Hou, Ruihua Dong

Source: BMC Chemistry, Vol 19, Iss 1, Pp 1-8 (2025)

Subject Terms: Pirtobrutinib, Pharmacokinetics, UHPLC-MS/MS, Zanubrutinib, Chemistry, QD1-999

File Description: electronic resource

Relation: https://doaj.org/toc/2661-801X

Access URL: https://doaj.org/article/dfc9e1fd46f74b5ea1a1ffbfc59f0637

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy

Authors: Nicole Lamanna, Constantine S. Tam, Jennifer A. Woyach, Alvaro J. Alencar, M. Lia Palomba, Pier Luigi Zinzani, Ian W. Flinn, Bita Fakhri, Jonathon B. Cohen, Arrin Kontos, Heiko Konig, Amy S. Ruppert, Anindya Chatterjee, Richard Sizelove, Livia Compte, Donald E. Tsai, Wojciech Jurczak

Source: eJHaem, Vol 5, Iss 5, Pp 929-939 (2024)

Subject Terms: antithrombotic therapy, B‐cell cancers, bleeding, Bruton tyrosine kinase inhibitor, pirtobrutinib, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2688-6146

Access URL: https://doaj.org/article/82cd9c8755ab4351873ea8a263b45176

PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia

Authors: Kong, Chunfang ^a, Wu, Mei ^a, Lu, Qilin ^a, Ke, Bo ^a, Xie, Jianhui ^b, Li, Anna ^{a, ⁎}

Source: In Leukemia Research September 2024 144

Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe

Authors: Enver Aydilek, Gerald Wulf, Friedrich Schwarz, Ulrike Bacher, Mathias Rummel, Olga Stiefel, Andrea Kerkhoff, Markus Maulhardt, Thomas Melchardt, Thomas Pabst, Georg Lenz, Evgenii Shumilov

Source: Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024)

Subject Terms: compassionate use program, mantle cell lymphoma, outcomes, pirtobrutinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/82ba4619d0c3405eb19265e1022f290e

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

Authors: Tambaro FP, De Novellis D, Wierda WG

Source: Journal of Experimental Pharmacology, Vol Volume 13, Pp 923-935 (2021)

Subject Terms: chronic lymphocytic leukemia, cll, bruton’s tyrosine kinase, btk, targeted therapy, ibrutinib, acalabrutinib, pirtobrutinib, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.dovepress.com/the-role-of-btk-inhibition-in-the-treatment-of-chronic-lymphocytic-leu-peer-reviewed-fulltext-article-JEP; https://doaj.org/toc/1179-1454

Access URL: https://doaj.org/article/986d7161af1b4df1b23594f692f378f6

Pirtobrutinib Yields Durable Efficacy in Pretreated Mantle Cell Lymphoma

Authors: By:Russ Conroy

Source: CancerNetwork (USA), January 10, 2024 News, 3pp

Pirtobrutinib Effective in Heavily Pretreated BTK–Mutated CLL

Authors: By:Courtney Flaherty

Source: CancerNetwork (USA), December 28, 2023 News, 5pp

Pirtobrutinib Yields Sustained Efficacy in R/R Mantle Cell Lymphoma

Authors: By:Nicholas Wrigley

Source: CancerNetwork (USA), June 12, 2023 News, 3pp

FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed/Refractory MCL

Authors: By:Russ Conroy

Source: CancerNetwork (USA), January 27, 2023 News, 2pp

Consortium Effort Drives Progress in Mantle Cell Lymphoma Research

Authors: By:Michael Wang, MD

Source: CancerNetwork (USA), February 9, 2024 News, 4pp

Avyakta Kallam, MD, on the Future of Mantle Cell Lymphoma

Authors: By:Avyakta Kallam, MD

Source: CancerNetwork (USA), August 21, 2023 News, 3pp

New England Journal of Medicine publishes BRUIN Phase 1/2 trial data for pirtobrutinib in BTK inhibitor pre-treated adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.

Source: Chemical Business NewsBase (UK), July 6, 2023, 3pp

Pirtobrutinib Elicits Responses in Heavily Pretreated Patients With CLL, SLL

Authors: By:Lindsay Fischer

Source: Oncology Nursing News (USA), July 12, 2023 News, 5pp

Lilly highlights Verzenio (abemaciclib) and Jaypirca (pirtobrutinib) Data at 2023 ASCO Annual Meeting.

Source: Chemical Business NewsBase (UK), June 2, 2023, 3pp

Summary of opinion: Jaypirca, pirtobrutinib, 26 Apr 2023, positive.

Source: Chemical Business NewsBase (UK), April 26, 2023, p. 1 2pp

BRUIN Trial: Pirtobrutinib for Patients With MCL

Authors: By:Andre H. Goy, MD

Source: CancerNetwork (USA), April 27, 2023 News, 2pp

Smith Discusses Importance of Adherence When Integrating Pirtobrutinib Into Clinical Practice

Authors: By:Megan Hollasch

Source: Oncology Nursing News (USA), March 7, 2023 News, 4pp

ASH Data Offer Treatment Direction for Oncology Nursing Professionals

Authors: By:Lindsay Fischer

Source: Oncology Nursing News (USA), February 1, 2023 News, 3pp

FDA Updates for the Week of Jan. 23, 2023

Authors: By:Denise Myshko

Source: Managed Healthcare Executive (USA), January 28, 2023 News, 5pp

FDA Approves Lilly's BTK Inhibitor for Rare Blood Cancer

Authors: By:Formulary Watch

Source: Formulary Watch (USA), January 27, 2023 News, 3pp